{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02323854",
      "orgStudyIdInfo": {
        "id": "COVEMPR0437"
      },
      "organization": {
        "fullName": "Medtronic - MITG",
        "class": "INDUSTRY"
      },
      "briefTitle": "The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)",
      "officialTitle": "The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)",
      "acronym": "EMPRESS"
    },
    "descriptionModule": {
      "briefSummary": "Post market prospective, non-randomized, single-arm, multicenter study, designed to demonstrate dose response of an ablation system using a percutaneous approach in patients with primary, metastatic, or recurrent primary lung tumors.",
      "detailedDescription": "Primary Endpoint: Dose response as indicated by CT imaging, measurement of maximum diameter and volume.\n\nSecondary Endpoint: Assessment of complete tumor ablation immediately post-procedure."
    },
    "conditionsModule": {
      "conditions": [
        "Lung Cancer"
      ],
      "keywords": [
        "primary, recurrent, metastatic lung tumor, ablation"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "SUPPORTIVE_CARE",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 15,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Ablation and Surgical Resection",
          "type": "OTHER",
          "description": "Ablation of lung tumor; followed by surgical resection of the ablation zone.",
          "interventionNames": [
            "Device: Ablation",
            "Procedure: Surgical Resection"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DEVICE",
          "name": "Ablation",
          "description": "Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.",
          "armGroupLabels": [
            "Ablation and Surgical Resection"
          ]
        },
        {
          "type": "PROCEDURE",
          "name": "Surgical Resection",
          "description": "The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.",
          "armGroupLabels": [
            "Ablation and Surgical Resection"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Dose Response",
          "description": "Dose response was assessed by comparing actual ablation zone size and volume to predicted ablation zone size and volume prescribed by the physician using the Emprint™ Procedure Planning Application. Dose response was measured for each ablation zone using CT imaging immediately post ablation and prior to the surgical resection.",
          "timeFrame": "1 Day"
        },
        {
          "measure": "Ablation Zone Shape",
          "description": "Ablation width (X) / height (Y), ratio of 1 indicates spherical ablation zone shape",
          "timeFrame": "Same day"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Number of Participants With Complete or Incomplete Tumor Ablation",
          "description": "The secondary endpoint was complete tumor ablation immediately post-procedure for each target tumor using histologic analysis. Complete ablation was defined as 100% nonviable tumor cells.",
          "timeFrame": "Same Day"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject or authorized representative has provided informed consent.\n* Subject is ≥18 years of age.\n* At least one pulmonary metastasis ≤ 3.0 cm in maximum diameter resulting from distant primary cancers or at least one recurrence of primary lung cancer ≤ 3.0 cm in maximum diameter.\n* Subject has been confirmed by a thoracic surgeon to be a surgical candidate for resection of the tumor targeted for ablation.\n* Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.\n* ≥1 cm of tumor-free lung parenchyma between target tumor and pleura or fissure.\n\nExclusion Criteria:\n\n* Pre-procedure Exclusion Criteria\n* Contraindicated for surgery.\n* Prolonged chest infection, defined as lung consolidation that requires hospitalization and greater than 10 days of antibiotics 30 days prior to surgery.\n* Tumor abutting main stem bronchus, main pulmonary artery branches, esophagus and/or trachea.\n* Tumor with pleural contact.\n* Tumors located \\< 3 cm of staple lines or other metal objects.\n* Patients diagnosed with GOLD Stage IV Emphysema.\n* Uncontrollable coagulopathy\n* Patients unable to tolerate discontinued use of anti-coagulants prior to and during the ablation procedure.\n* Subject is pregnant (documented by a positive pregnancy test according to hospital standard practices) or is actively breast-feeding.\n* Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study.\n* The investigator determines that participation in the study may jeopardize the safety or welfare of the subject.\n* Patients with implantable pacemakers and other electronic implants, in accordance with Instructions for Use (IFU).\n\nIntraprocedural Exclusion Criteria\n\n\\*Incidental intraprocedural finding that the subject no longer meets the study eligibility criteria.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    }
  }
}